Managed Asset Portfolios LLC Purchases 79,686 Shares of Sanofi SA (NYSE:SNY)

Managed Asset Portfolios LLC raised its position in Sanofi SA (NYSE:SNY) by 14.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 612,855 shares of the company’s stock after purchasing an additional 79,686 shares during the quarter. Sanofi comprises approximately 6.2% of Managed Asset Portfolios LLC’s investment portfolio, making the stock its 4th biggest holding. Managed Asset Portfolios LLC’s holdings in Sanofi were worth $28,394,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Thomasville National Bank boosted its holdings in shares of Sanofi by 3.3% in the second quarter. Thomasville National Bank now owns 33,494 shares of the company’s stock valued at $1,449,000 after acquiring an additional 1,060 shares in the last quarter. Carroll Financial Associates Inc. boosted its holdings in shares of Sanofi by 89.1% in the second quarter. Carroll Financial Associates Inc. now owns 2,736 shares of the company’s stock valued at $118,000 after acquiring an additional 1,289 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Sanofi by 1.6% in the second quarter. Crossmark Global Holdings Inc. now owns 62,474 shares of the company’s stock valued at $2,703,000 after acquiring an additional 980 shares in the last quarter. Zions Bancorporation N.A. boosted its holdings in shares of Sanofi by 28.4% in the second quarter. Zions Bancorporation N.A. now owns 1,827 shares of the company’s stock valued at $79,000 after acquiring an additional 404 shares in the last quarter. Finally, Patten Group Inc. boosted its holdings in shares of Sanofi by 3.5% in the second quarter. Patten Group Inc. now owns 7,179 shares of the company’s stock valued at $311,000 after acquiring an additional 240 shares in the last quarter. Institutional investors own 7.04% of the company’s stock.

In related news, major shareholder Sanofi sold 172,904 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.00% of the company’s stock.

NYSE:SNY traded up $0.38 during trading hours on Friday, reaching $45.86. 1,914,762 shares of the company’s stock were exchanged, compared to its average volume of 1,307,250. The company has a market capitalization of $114.86 billion, a P/E ratio of 14.65, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. Sanofi SA has a 12 month low of $40.00 and a 12 month high of $47.47. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The business’s 50-day simple moving average is $45.83 and its two-hundred day simple moving average is $43.35.

Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Thursday, August 29th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Monday, October 14th. Morgan Stanley upgraded shares of Sanofi from an “equal” rating to a “weight” rating in a report on Friday, September 20th. Sanford C. Bernstein initiated coverage on shares of Sanofi in a report on Tuesday, September 3rd. They set an “outperform” rating and a $52.00 target price for the company. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Thursday, August 29th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $49.67.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: Inverted Yield Curve

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.